GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Cyclically Adjusted Revenue per Share

United Therapeutics (STU:UTH) Cyclically Adjusted Revenue per Share : €39.87 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is United Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

United Therapeutics's adjusted revenue per share for the three months ended in Sep. 2024 was €13.941. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €39.87 for the trailing ten years ended in Sep. 2024.

During the past 12 months, United Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of United Therapeutics was 35.70% per year. The lowest was 11.40% per year. And the median was 23.20% per year.

As of today (2024-12-12), United Therapeutics's current stock price is €344.70. United Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was €39.87. United Therapeutics's Cyclically Adjusted PS Ratio of today is 8.65.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 15.95. The lowest was 2.88. And the median was 5.90.


United Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for United Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Cyclically Adjusted Revenue per Share Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.65 24.12 29.94 35.24 37.13

United Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.88 37.13 41.10 41.25 39.87

Competitive Comparison of United Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, United Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PS Ratio falls into.



United Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=13.941/133.0289*133.0289
=13.941

Current CPI (Sep. 2024) = 133.0289.

United Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 5.229 99.070 7.021
201503 6.480 99.621 8.653
201506 5.961 100.684 7.876
201509 6.855 100.392 9.084
201512 7.479 99.792 9.970
201603 6.804 100.470 9.009
201606 7.830 101.688 10.243
201609 7.872 101.861 10.281
201612 8.559 101.863 11.178
201703 7.547 102.862 9.760
201706 8.813 103.349 11.344
201709 8.476 104.136 10.828
201712 8.924 104.011 11.414
201803 7.190 105.290 9.084
201806 8.767 106.317 10.970
201809 8.038 106.507 10.040
201812 7.619 105.998 9.562
201903 7.343 107.251 9.108
201906 7.514 108.070 9.249
201909 8.286 108.329 10.175
201912 6.392 108.420 7.843
202003 7.312 108.902 8.932
202006 7.240 108.767 8.855
202009 7.236 109.815 8.766
202012 7.000 109.897 8.473
202103 6.863 111.754 8.169
202106 7.835 114.631 9.092
202109 7.941 115.734 9.128
202112 7.671 117.630 8.675
202203 8.793 121.301 9.643
202206 9.183 125.017 9.772
202209 10.701 125.227 11.368
202212 9.392 125.222 9.978
202303 9.545 127.348 9.971
202306 11.123 128.729 11.495
202309 11.489 129.860 11.769
202312 11.274 129.419 11.588
202403 12.545 131.776 12.664
202406 13.982 132.554 14.032
202409 13.941 133.029 13.941

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


United Therapeutics  (STU:UTH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=344.70/39.87
=8.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 15.95. The lowest was 2.88. And the median was 5.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


United Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics Headlines

No Headlines